WO2022078490A1 - Anticorps anti-erbb3 ou fragment de liaison à l'antigène de celui-ci et utilisation médicale associée - Google Patents

Anticorps anti-erbb3 ou fragment de liaison à l'antigène de celui-ci et utilisation médicale associée Download PDF

Info

Publication number
WO2022078490A1
WO2022078490A1 PCT/CN2021/124031 CN2021124031W WO2022078490A1 WO 2022078490 A1 WO2022078490 A1 WO 2022078490A1 CN 2021124031 W CN2021124031 W CN 2021124031W WO 2022078490 A1 WO2022078490 A1 WO 2022078490A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
antibody
antigen
erbb3
binding fragment
Prior art date
Application number
PCT/CN2021/124031
Other languages
English (en)
Chinese (zh)
Inventor
何娟梅
张莉
谢岳峻
Original Assignee
上海翰森生物医药科技有限公司
江苏豪森药业集团有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海翰森生物医药科技有限公司, 江苏豪森药业集团有限公司 filed Critical 上海翰森生物医药科技有限公司
Priority to CN202180050433.6A priority Critical patent/CN115843256A/zh
Publication of WO2022078490A1 publication Critical patent/WO2022078490A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to an ERBB3 antibody or an antigen-binding fragment thereof, furthermore, the present invention relates to a fully human ERBB3 antibody or an antigen-binding fragment thereof comprising a CDR region; the present invention also relates to an antibody comprising the fully human ERBB3 antibody or an antigen-binding fragment thereof Pharmaceutical compositions, and their use as diagnostics and therapeutics for ERBB3-related diseases.
  • ERBB receptor is widely expressed in neuronal cells, epithelial cells, and mesenchymal cells, and is involved in the development of cardiovascular, neural, musculoskeletal and other organs, and is involved in cancer pathogenesis.
  • ERBB receptor has 4 family proteins: EGFR, ERBB2, ERBB3 and ERBB4, all of which are membrane proteins with similar molecular structure, including extracellular domain (ECD), transmembrane domain, intracellular domain with tyrosine kinase activity, and C-terminal.
  • ECD extracellular domain
  • transmembrane domain transmembrane domain
  • intracellular domain with tyrosine kinase activity and C-terminal.
  • the ECD can be subdivided into 4 subdomains: subdomains I, II, III, IV (BMC Bioinformatics 2001, 2:4.; Mol Cell 2003, 11:507-17.), where I and III are leucine-rich, is the ligand-binding domain; II and IV are cysteine-rich and dimer-forming domains. Except for ERBB2, the other three ERBB receptors bind II and IV in the inactive state, and only open when they are bound and activated by ligands, exposing II to form dimers. At present, there are many studies on EGFR and ERBB2, and the development of corresponding targeted drugs is relatively intensive. In recent years, the attention of ERBB3 has been continuously increased.
  • ERBB3 bypass plays a key role, and ERBB3 is involved in breast, lung, prostate, colorectal, ovarian, gastric, and bladder cancers. , melanoma and other tumors have high expression, so ERBB3 is another potential target for tumor therapy.
  • ERBB3 has two ligands, NRG1 and NRG2. The ligands can activate the kinase activity of ERBB3.
  • the activated ERBB3 can form a heterodimer with EGFR or ERBB2 and phosphorylate the latter, thereby transmitting signals to downstream pathways to promote Growth and proliferation of tumor cells.
  • ERBB3 can also transmit signals through "cross talk" with other RTKs, such as forming a complex with IGF1R, FGFR2 and HGFR(c-Met) (BioDrugs 2017, 31:63-73), it can be seen that ERBB3 plays an important role in tumors. important role in growth.
  • ERBB3-targeted therapy can include: monoclonal antibodies, bispecific antibodies, vaccines against ERBB3, ligand traps, RNA inhibitors that lock ERBB3, and small molecules that inhibit ERBB3 kinase activity.
  • monoclonal antibodies bispecific antibodies
  • vaccines against ERBB3, ligand traps RNA inhibitors that lock ERBB3, and small molecules that inhibit ERBB3 kinase activity.
  • RNA inhibitors that lock ERBB3
  • small molecules that inhibit ERBB3 kinase activity the research and development of antibodies targeting ERBB3 is relatively high.
  • ERBB3 antibody significantly inhibited the growth of patient tumors (citing Celldex data).
  • the ERBB3 antibodies currently under development are humanized antibodies that have been humanized and modified from mouse-derived antibodies, and the immunogenicity of humanized antibodies during immunization is higher than that of fully human antibodies without mouse-derived antibody components.
  • Human application is a disadvantage; some ERBB3 antibody drugs under development are fully human antibodies obtained by phage library display technology, which can solve the problem of immunogenicity.
  • Phage display technology is the fusion expression of foreign proteins or polypeptides with phage coat proteins, thereby expressing foreign proteins on the surface of phage.
  • Phage antibody library is an antibody library established by a comprehensive technical means combining phage display technology, PCR amplification technology and protein expression technology.
  • Phage libraries generally include synthetic libraries, immune libraries, and natural libraries.
  • the natural library is the most widely used.
  • the natural library is usually a fully human antibody library constructed from immune cells of human peripheral blood. In vivo immunization, however, a highly diverse fully human antibody that has been produced by the human body can be obtained.
  • the phage antibody library also has the following advantages: (1) The unification of genotype and phenotype is achieved.
  • the experimental method is simple and fast, the traditional method of antibody production by hybridoma technology takes months, while the antibody library technology only takes a few weeks. 2 It expresses fully human antibodies with small molecular weight, mainly in the form of active fragments Fab and scFV, which have obvious advantages in tissue penetration compared with complete antibodies.
  • Hybridoma technology can screen thousands of clones, and antibody library technology can select millions or even hundreds of millions of molecules. There are more types of antibodies screened. 4It has a wide range of uses and adopts a prokaryotic expression system, which has more obvious advantages in large-scale production (Curr Opin Biotechnol. 2002 Dec; 13(6): 598-602; Immunotechnology, 2013, 48(13) 48(13): 63- 73).
  • the present invention provides an anti-ERBB3 antibody or an antigen-binding fragment thereof, in particular to a fully human anti-ERBB3 antibody or an antigen-binding fragment thereof, the anti-ERBB3 antibody or an antigen-binding fragment thereof comprising: an antibody heavy chain variable region and light chain variable region; wherein, the antibody heavy chain variable region comprises at least one HCDR selected from the following sequences: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 3 ID NO: 4; the antibody light chain variable region comprises at least one LCDR selected from the following sequences: SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 7.
  • the present invention also relates to a preferred solution, an anti-ERBB3 antibody or an antigen-binding fragment thereof as described above, wherein:
  • the antibody heavy chain variable region comprises HCDR1 shown in SEQ ID NO: 1, HCDR2 shown in SEQ ID NO: 2, and HCDR3 shown in SEQ ID NO: 4; or,
  • the antibody heavy chain variable region comprises HCDR1 shown in SEQ ID NO:1, HCDR2 shown in SEQ ID NO:3, and HCDR3 shown in SEQ ID NO:4.
  • the present invention also relates to a preferred embodiment, an anti-ERBB3 antibody or an antigen-binding fragment thereof as described above, wherein the antibody light chain variable region comprises:
  • LCDR1 shown in SEQ ID NO:5 LCDR2 shown in SEQ ID NO:6, and LCDR3 shown in SEQ ID NO:7.
  • the present invention also relates to a preferred embodiment, an anti-ERBB3 antibody or an antigen-binding fragment thereof as described above, comprising a heavy chain variable region and a light chain variable region, wherein:
  • variable region of the antibody heavy chain comprises HCDR1 shown in SEQ ID NO:1, HCDR2 shown in SEQ ID NO:2, and HCDR3 shown in SEQ ID NO:4; the antibody light chain can be The variable region comprises LCDR1 shown in SEQ ID NO:5, LCDR2 shown in SEQ ID NO:6, and LCDR3 shown in SEQ ID NO:7.
  • the present invention also relates to a preferred embodiment, an anti-ERBB3 antibody or an antigen-binding fragment thereof as described above, comprising a heavy chain variable region and a light chain variable region, wherein:
  • variable region of the antibody heavy chain comprises: HCDR1 shown in SEQ ID NO:1, HCDR2 shown in SEQ ID NO:3, and HCDR3 shown in SEQ ID NO:4; the antibody light chain variable region The regions include: LCDR1 shown in SEQ ID NO:5, LCDR2 shown in SEQ ID NO:6, and LCDR3 shown in SEQ ID NO:7.
  • the present invention also relates to a preferred embodiment, an anti-ERBB3 antibody or an antigen-binding fragment thereof as described above, wherein the heavy chain variable region of the antibody is selected from the heavy chain variable regions shown in the following sequence: SEQ ID NO:8 or SEQ ID NO:9.
  • the present invention also relates to a preferred embodiment, an anti-ERBB3 antibody or an antigen-binding fragment thereof as described above, wherein the variable region of the antibody light chain is SEQ ID NO: 10.
  • the present invention also relates to a preferred embodiment, an anti-ERBB3 antibody or an antigen-binding fragment thereof as described above, wherein the antibody comprises: the heavy chain variable region shown in SEQ ID NO:8, and SEQ ID NO:10 The light chain variable region shown; or,
  • the anti-ERBB3 antibody or antigen-binding fragment thereof comprises the heavy chain variable region shown in SEQ ID NO:9, and the light chain variable region shown in SEQ ID NO:10.
  • the anti-ERBB3 antibody or its antigen-binding fragment further comprises the heavy chain constant region of human IgG1 or its variant;
  • the anti-ERBB3 antibody or its antigen-binding fragment further comprises a human IgG1 heavy chain constant region
  • the anti-ERBB3 antibody or its antigen-binding fragment further comprises a light chain constant region derived from human ⁇ chain, ⁇ chain or a mutant thereof;
  • the anti-ERBB3 antibody or antigen-binding fragment thereof comprises a heavy chain variable region selected from the group consisting of: SEQ ID NO: 8, SEQ ID NO: 9, or a heavy chain variable region having at least 70%, 75%, 80%, 85%, 90%, 95% or 99% homology therewith.
  • the present invention also relates to a preferred embodiment, an anti-ERBB3 antibody or an antigen-binding fragment thereof as described above, wherein the heavy chain of the antibody is selected from heavy chains containing the following sequences: SEQ ID NO: 11 or SEQ ID NO: 12.
  • the anti-ERBB3 antibody comprises the heavy chain shown in SEQ ID NO: 11, and the light chain shown in SEQ ID NO: 13; or,
  • the anti-ERBB3 antibody comprises the heavy chain shown in SEQ ID NO:12, and the light chain shown in SEQ ID NO:13.
  • the present invention also relates to a preferred embodiment, an anti-ERBB3 antibody or an antigen-binding fragment thereof as described above, wherein the anti-ERBB3 antibody or an antigen-binding fragment thereof comprises a heavy chain selected from the group consisting of: SEQ ID NO: 11, SEQ ID NO: 12, or a full-length heavy chain having at least 80%, 85%, 90%, 95%, or 99% homology thereto.
  • the present invention also relates to a preferred embodiment, an anti-ERBB3 antibody or an antigen-binding fragment thereof as described above, wherein the anti-ERBB3 antibody or antigen-binding fragment thereof comprises the light chain SEQ ID NO: 13, or has at least 80%, Full-length light chains of 85%, 90%, 95% or 99% homology.
  • the present invention further provides a polynucleotide encoding the above-mentioned anti-ERBB3 antibody or an antigen-binding fragment thereof.
  • the present invention further provides an expression vector containing the above-mentioned polynucleotide.
  • the present invention further provides a host cell into which the above-mentioned expression vector is introduced or contained.
  • the above-mentioned host cells are bacteria, preferably Escherichia coli.
  • the present invention further provides a method for producing an anti-ERBB3 antibody or an antigen-binding fragment thereof, comprising the steps of:
  • the present invention further provides a pharmaceutical composition
  • a pharmaceutical composition comprising the above-mentioned anti-ERBB3 antibody or antigen-binding fragment thereof, and a pharmaceutically acceptable excipient, diluent or carrier.
  • the present invention further provides a detection or diagnostic reagent, which contains the above-mentioned anti-ERBB3 antibody or its antigen-binding fragment and an excipient, diluent or carrier that can be used for detection or diagnosis.
  • the present invention further provides use of the above-mentioned anti-ERBB3 antibody or an antigen-binding fragment thereof or the above-mentioned composition in the preparation of a medicament for the treatment or prevention of ERBB3-mediated diseases or disorders.
  • the present invention further provides use of the above-mentioned anti-ERBB3 antibody or antigen-binding fragment thereof or the above-mentioned detection or diagnosis reagent in the preparation of a reagent, wherein the reagent is used to detect, diagnose and predict ERBB3-mediated diseases or conditions.
  • the aforementioned disease or condition is cancer
  • breast cancer More preferably breast cancer, ovarian cancer, prostate cancer, endometrial cancer, thyroid cancer, kidney cancer, lung cancer, stomach cancer, colon cancer, bladder cancer, cervical cancer, gallbladder cancer, pancreatic cancer, testicular cancer, soft tissue sarcoma, head and neck cancer cancer, glioma, or melanoma.
  • the above-mentioned anti-ERBB3 antibody or its antigen-binding fragment or the above-mentioned composition is used for detecting, diagnosing and prognosing ERBB3-mediated diseases; the diseases are selected from breast cancer, ovarian Cancer, Prostate Cancer, Endometrial Cancer, Thyroid Cancer, Kidney Cancer, Lung Cancer, Stomach Cancer, Colon Cancer, Bladder Cancer, Cervical Cancer, Gallbladder Cancer, Pancreatic Cancer, Testicular Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, Glioma or melanoma.
  • the present invention further provides a method for treating or preventing ERBB3-mediated diseases, comprising the steps of:
  • a therapeutically effective amount or a prophylactically effective amount of the above-mentioned anti-ERBB3 antibody or an antigen-binding fragment thereof is provided to a subject; or the above-mentioned pharmaceutical composition of a therapeutically effective amount or a prophylactically effective amount is provided to the subject; wherein the ERBB3 mediates
  • the disease is selected from: breast cancer, ovarian cancer, prostate cancer, endometrial cancer, thyroid cancer, kidney cancer, lung cancer, stomach cancer, colon cancer, bladder cancer, cervical cancer, gallbladder cancer, pancreatic cancer, testicular cancer, soft tissue sarcoma, Head and neck cancer, glioma or melanoma.
  • IgG can be divided into different subclasses according to the difference in the amino acid composition of the hinge region and the number and position of disulfide bonds in the heavy chain.
  • IgG can be divided into IgG1, IgG2, IgG3, and IgG4.
  • Light chains are classified into kappa chains or lambda chains by the difference in the constant region.
  • Each of the five classes of Ig can have a kappa chain or a lambda chain.
  • the antibody light chain variable region of the present invention may further comprise a light chain constant region comprising human or murine ⁇ , ⁇ chains or variants thereof.
  • the antibody heavy chain variable region of the present invention may further comprise a heavy chain constant region comprising human or murine IgG1, IgG2, IgG3, IgG4 or variants thereof.
  • variable region The sequence of about 110 amino acids near the N-terminus of the antibody heavy and light chains varies greatly, which is the variable region (V region); the remaining amino acid sequences near the C-terminus are relatively stable and are the constant region (C region).
  • the variable region includes three hypervariable regions (HVR) and four relatively conserved framework regions (FR). Three hypervariable regions determine the specificity of antibodies, also known as complementarity determining regions (CDRs).
  • CDRs complementarity determining regions
  • Each light chain variable region (VL) and heavy chain variable region (VH) are composed of 3 CDR regions and 4 FR regions. The order from the amino terminus to the carboxyl terminus is: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • APC antigen presenting cell
  • DCs dendritic cells
  • PBMCs topical blood mononuclear cells
  • monocytes B lymphoblasts
  • monocyte-derived dendritic cells monocyte-derived dendritic cells
  • antigen presentation refers to the process by which APCs capture antigens and enable their recognition by T cells, eg, as a component of MHC-I/MHC-II conjugates.
  • recombinant human antibody includes human antibodies prepared, expressed, created or isolated by recombinant methods, involving techniques and methods well known in the art, such as:
  • Antibodies isolated from host cells transformed to express the antibodies such as transfectomas;
  • Antibodies prepared, expressed, created or isolated by methods such as splicing human immunoglobulin gene sequences into other DNA sequences.
  • Such recombinant human antibodies contain variable and constant regions that utilize specific human germline immunoglobulin sequences encoded by germline genes, but also include subsequent rearrangements and mutations such as those that occur during antibody maturation.
  • human antibody includes antibodies having variable and constant regions of human germline immunoglobulin sequences.
  • Human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (eg, mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo).
  • the term “human antibody” does not include antibodies in which CDR sequences derived from the germline of another mammalian species (such as a mouse) have been grafted onto human backbone sequences (ie, "humanized antibodies”) .
  • antigen-binding fragment refers to antigen-binding fragments and antibody analogs of antibodies, which typically include at least a portion of the antigen-binding or variable regions (eg, one or more CDRs) of the parental antibody.
  • Antibody fragments retain at least some of the binding specificity of the parent antibody. Typically, antibody fragments retain at least 10% of the parent binding activity when the activity is expressed on a molar basis. Preferably, the antibody fragment retains at least 20%, 50%, 70%, 80%, 90%, 95% or 100% or more of the binding affinity of the parent antibody for the target.
  • antigen-binding fragments include, but are not limited to: Fab, Fab', F(ab')2, Fv fragments, linear antibodies, single chain antibodies, Nanobodies, domain antibodies, and multispecific antibodies. Engineered antibody variants are reviewed in Holliger and Hudson, 2005, Nat. Biotechnol. 23: 1126-1136.
  • Fab fragment consists of the CH1 and variable regions of one light chain and one heavy chain.
  • the heavy chain of a Fab molecule cannot form a disulfide bond with another heavy chain molecule.
  • Fc region contains two heavy chain fragments comprising the CH1 and CH2 domains of an antibody.
  • the two heavy chain fragments are held together by two or more disulfide bonds and by hydrophobic interactions of the CH3 domains.
  • Fab' fragment contains a light chain and a portion of a heavy chain comprising the VH and CH1 domains and the region between the CH1 and CH2 domains, and thus can be located between the two heavy chains of two Fab' fragments. Interchain disulfide bonds are formed between them to form F(ab')2 molecules.
  • F(ab')2 fragment contains two light chains and two heavy chains comprising part of the constant region between the CH1 and CH2 domains, thereby forming an interchain disulfide bond between the two heavy chains.
  • an F(ab')2 fragment consists of two Fab' fragments held together by disulfide bonds between the two heavy chains.
  • Fv region includes variable regions from both heavy and light chains, but lacks the constant regions.
  • multispecific antibody is used in its broadest sense to encompass antibodies with specificity for multiple epitopes.
  • These multispecific antibodies include, but are not limited to: antibodies comprising a heavy chain variable region VH and a light chain variable region VL, wherein the VH-VL unit has polyepitope specificity; having two or more VL and VH regions antibodies, each VH-VL unit binds to a different target or a different epitope of the same target; antibodies with two or more single variable domains, each single variable domain to a different target or different epitopes of the same target; full-length antibodies, antibody fragments, diabodies, bispecific diabodies and triabodies, antibody fragments covalently or non-covalently linked together Wait.
  • single-chain antibody is a single-chain recombinant protein formed by linking the heavy chain variable region VH and light chain variable region VL of an antibody through a linking peptide, which is the smallest antibody fragment with a complete antigen-binding site.
  • domain antibody fragment is an immunologically functional immunoglobulin fragment containing only the variable region of the heavy chain or the variable region of the light chain.
  • two or more VH regions are covalently linked to a peptide linker to form a bivalent domain antibody fragment.
  • the two VH regions of a bivalent domain antibody fragment can target the same or different antigens.
  • binding to ERBB3 refers to the ability to interact with human ERBB3.
  • antigen-binding site refers to a site in three-dimensional space recognized by an antibody or antigen-binding fragment of the invention.
  • epitopes refers to the site on an antigen to which an immunoglobulin or antibody specifically binds.
  • Epitopes can be formed by adjacent amino acids, or non-adjacent amino acids juxtaposed by tertiary folding of the protein. Epitopes formed by adjacent amino acids are typically retained upon exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost upon treatment with denaturing solvents.
  • Epitopes typically include at least 3-15 amino acids in a unique spatial conformation. Methods for determining what epitopes are bound by a given antibody are well known in the art and include immunoblotting and immunoprecipitation assays, among others. Methods for determining the spatial conformation of epitopes include techniques in the art and those described herein, such as X-ray crystallography and two-dimensional nuclear magnetic resonance, among others.
  • the terms “specifically binds” and “selectively binds” refer to the binding of an antibody to a predetermined epitope on an antigen.
  • the antibody exhibits an equilibrium dissociation constant ( K D ) binds to a predetermined antigen with an affinity that is at least twice as high as its binding affinity to a non-specific antigen other than the predetermined antigen or a closely related antigen (eg, BSA, etc.).
  • K D equilibrium dissociation constant
  • the term “antibody that recognizes an antigen” is used interchangeably herein with the term “antibody that specifically binds”.
  • cross-reactivity refers to the ability of an antibody of the invention to bind to ERBB3 from different species.
  • an antibody of the invention that binds to human ERBB3 can also bind to ERBB3 of another species.
  • Cross-reactivity is measured by detecting specific reactivity with purified antigen in binding assays (eg SPR and ELISA), or binding or functional interaction with cells that physiologically express ERBB3.
  • binding assays eg SPR and ELISA
  • Methods to determine cross-reactivity include standard binding assays as described herein, such as surface plasmon resonance (SPR) analysis, or flow cytometry.
  • SPR surface plasmon resonance
  • inhibitor or “block” are used interchangeably and encompass both partial and complete inhibition/blocking. Inhibition/blocking of the ligand preferably reduces or alters the normal level or type of activity that occurs when ligand binding occurs without inhibition or blocking. Inhibition and blocking are also intended to include any measurable reduction in ligand binding affinity when contacted with an anti-ERBB3 antibody compared to a ligand not contacted with an anti-ERBB3 antibody.
  • inhibiting growth eg, in relation to a cell
  • inhibiting growth is intended to include any measurable reduction in cell growth.
  • the "ADCC” in the present invention namely antibody-dependent cell-mediated cytotoxicity, refers to that the cells expressing Fc receptors are directly killed by the antibody-coated cells by recognizing the Fc segment of the antibody. target cells.
  • the ADCC effector function of the antibody can be reduced or eliminated by enhancing or reducing the modification of the Fc segment of IgG.
  • the modification refers to mutation in the constant region of the heavy chain of the antibody.
  • the engineered antibodies or antigen-binding fragments of the invention can be prepared and purified using conventional methods.
  • the cDNA sequences of the corresponding antibodies can be cloned and recombined into GS expression vectors.
  • the recombinant immunoglobulin expression vector can stably transfect CHO cells.
  • mammalian-like expression systems lead to glycosylation of the antibody, especially at the highly conserved N-terminus of the FC region.
  • Stable clones are obtained by expressing antibodies that specifically bind to human antigens. Positive clones were expanded in serum-free medium in bioreactors for antibody production.
  • the antibody-secreted culture medium can be purified and collected by conventional techniques.
  • Antibodies can be filtered and concentrated by conventional methods. Soluble mixtures and polymers can also be removed by conventional methods, such as molecular sieves, ion exchange.
  • the obtained product should be frozen immediately, eg -70°C, or lyophilized.
  • administering when applied to animals, humans, experimental subjects, cells, tissues, organs, or biological fluids, refer to exogenous drugs, therapeutic agents, diagnostic agents, or compositions that interact with the animal. , contact of humans, subjects, cells, tissues, organs or biological fluids.
  • administering can refer to, for example, therapeutic, pharmacokinetic, diagnostic, research, and experimental methods.
  • Treatment of cells includes contact of reagents with cells, and contact of reagents with fluids, wherein the fluids are in contact with cells.
  • administering also mean in vitro and ex vivo treatment of, eg, cells by an agent, diagnostic, binding composition, or by another cell.
  • Treatment when applied to human, veterinary or research subjects refers to therapeutic treatment, prophylactic or preventive measures, research and diagnostic applications.
  • Treatment means administering an internal or external therapeutic agent, such as comprising any of the antibodies of the invention, to a patient having one or more symptoms of a disease for which the therapeutic agent is known to have a therapeutic effect.
  • the therapeutic agent is administered in an amount effective to alleviate one or more symptoms of a disease in a patient or population to be treated, either by inducing regression of such symptoms or inhibiting the progression of such symptoms to any clinically measured degree.
  • the amount of a therapeutic agent effective to relieve symptoms of any particular disease can vary depending on factors such as the patient's disease state, age and weight, and the ability of the drug to produce the desired effect in the patient.
  • Whether symptoms of a disease have been alleviated can be assessed by any clinical test commonly used by doctors or other health care professionals to assess the severity or progression of the symptoms.
  • embodiments of the invention e.g., methods of treatment or articles of manufacture
  • naturally occurring refers to the fact that the object can be found in nature.
  • a polypeptide sequence or a polynucleotide sequence that exists in an organism (including a virus) that can be isolated from natural sources and has not been intentionally modified artificially in the laboratory is naturally occurring.
  • an “effective amount” includes an amount sufficient to ameliorate or prevent the symptoms or conditions of the medical condition.
  • An effective amount also means an amount sufficient to allow or facilitate diagnosis.
  • the effective amount for a particular patient or veterinary subject may vary depending on factors such as the condition being treated, the general health of the patient, the method, route and dosage of administration, and the severity of side effects.
  • An effective amount can be the maximum dose or dosing regimen that avoids significant side effects or toxic effects.
  • Exogenous refers to a substance that is to be produced outside of an organism, cell or human in context.
  • Endogenous refers to a substance produced in a cell, organism or human body depending on the context.
  • “Homology” refers to the sequence similarity between two polynucleotide sequences or between two polypeptides. Two DNA molecules are homologous when a position in the two compared sequences is occupied by the same base or amino acid monomer subunit, for example if each position is occupied by an adenine, then the molecules are homologous at that position .
  • the percent homology between the two sequences is a function of the number of matches or homologous positions shared by the two sequences divided by the number of positions compared x 100%. For example, when sequences are optimally aligned, two sequences are 60% homologous if 6 of 10 positions in the two sequences are matched or homologous. In general, comparisons are made when the two sequences are aligned for the greatest percent homology.
  • the expressions "cell”, “cell line” and “cell culture” are used interchangeably and all such designations include progeny thereof.
  • the words “transformants” and “transformed cells” include primary test cells and cultures derived therefrom, regardless of the number of transfers. It should also be understood that, due to deliberate or unintentional mutations, all progeny may not be exactly the same in terms of DNA content. Mutant progeny that have the same function or biological activity as screened in the original transformed cell are included. Where a different name is meant, it is clear from the context.
  • “Pharmaceutical composition” means containing one or more of the antibodies or antigen-binding fragments thereof described herein, together with other components such as physiological/pharmaceutically acceptable carriers and excipients.
  • the purpose of the pharmaceutical composition is to facilitate the administration to the organism, facilitate the absorption of the active ingredient and then exert the biological activity.
  • the amino acid sequence of the human ERBB3 protein shown in SEQ ID NO: 14 was used as the template for designing the antigen of the present invention.
  • the following ERBB3 antigens without special description refer to human ERBB3.
  • ERBB3 full-length protein: ERBB3 (SEQ ID NO: 14) sequence is as follows:
  • the ERBB3 antigen used for screening is a commercial product Biotinylated human ERBB3-His tag (Sino biological, cat# 10201-H08H-B); the ERBB3 antigen used for detection is a commercial product human ERBB3-His tag (Sino biological, cat# 10201-H08H) .
  • the ERBB3 antigen used for detection is the ECD region sequence of human ERBB3 with a His tag at the C-terminus, and the ERBB3 antigen used for screening is biotinylated on this basis.
  • the ECD sequence of human ERBB3 is as follows:
  • the monkey ERBB3 antigen (SEQ ID NO: 16) used for the detection is the commercial product Rhesus ERBB3 Protein-His Tag (Sino biological, cat# 90043-K08H), which is the ECD region sequence of the monkey ERBB3 antigen with His tag added at the C-terminus. as follows:
  • PBMCs Multiple human PBMCs were collected, B cells were isolated, RNA was extracted, reverse transcribed into cDNA, and then a natural phage surface Fab display library (library capacity 1.6 ⁇ 10 11 ) was constructed using the cDNA as a template.
  • the constructed natural Fab phage library was packaged to form phage particles, and then panned by liquid phase method.
  • the phage was combined with biotinylated ERBB3 in liquid phase, and then separated by streptavidin magnetic beads.
  • biotinylated human ERBB3 was used for 2-3 rounds of panning, and 384 monoclonal colonies were picked and packaged into phage-displayed Fab fragments for ELISA test.
  • the obtained heavy chain and light chain variable region sequences are respectively connected with the human IgG1 heavy chain constant region and light chain constant region sequences to obtain full-length antibodies, and these full-length antibodies are subjected to experimental evaluation to finally determine a binding force and Antibody Ab1 with better functions; wherein, the connected human IgG1 heavy chain constant region and light chain constant region sequences are shown in SEQ ID NO: 17 and SEQ ID NO: 18, respectively.
  • the IgG1 heavy chain constant region and light chain constant region sequences are as follows:
  • cDNA fragments were synthesized from the amino acid sequences of the light and heavy chains of Ab1 and Ab2 antibodies and inserted into the pcDNA3.1 expression vector (Life Technologies Cat. No. V790-20).
  • the expression vector and transfection reagent PEI Polysciences, Inc. Cat. No. 23966 were transfected into HEK293 cells (Life Technologies Cat. No. 11625019) at a ratio of 1: 2 and incubated in a CO incubator for 4- 5 days.
  • the cell culture medium was collected, and after centrifugal filtration, the sample was applied to the antibody purification affinity column, and the column was washed with phosphate buffer, eluted with glycine hydrochloric acid buffer (pH2.7 0.1M Gly-HCl), neutralized with 1M Tris hydrochloric acid pH 9.0, and Phosphate buffer dialysis to obtain the antibody protein of the present invention, and its concentration and purity are as shown in Table 5:
  • Human ERBB3His protein (Sino biological, cat# 10201-H08H), monkey ERBB3 His protein (Sino biological, cat# 90043-K08H), murine ERBB3 His protein (Sino biological, cat# 51003-M08H) were mixed with PBS at pH 7.4.
  • human EGFR His protein (Sino biological, cat# 10001-H08H), human ERBB2 His protein (Sino biological, cat# 10004-H08H), human ERBB4 His protein (Sino biological, cat# 10363-H08H) were diluted to 0.5 ⁇ g respectively /mL concentration, add 100 ⁇ L/well to 96-well high-affinity ELISA plate, and incubate at 4°C overnight (16-20 hours). After washing the plate 3 times with PBST (pH 7.4 PBS containing 0.05% Tween-20), 200 ⁇ L/well of 1% bovine serum albumin (BSA) blocking solution diluted with PBST was added and incubated at 37°C for 2 hours for blocking. After blocking, the blocking solution was discarded, and the plate was washed once with PBST buffer.
  • BSA bovine serum albumin
  • the antibody to be tested was diluted with PBST containing 1% BSA, starting at 10 nM, 3-fold serial dilution, 11 doses, added to the ELISA plate at 100 ⁇ L/well, and incubated at 37° C. for 1 hour. After the incubation, the plate was washed three times with PBST, and 200 ⁇ L/well of secondary antibody anti-human HRP (Abeam, cat# ab97225) diluted with PBST containing 1% BSA was added, and incubated at 37°C for 0.5 hours.
  • TMB chromogenic substrate (Suzhou Yake Chemical Reagent Co., Ltd., cat# S0025), incubate at 25°C for 8-15 minutes in the dark, and add 50 ⁇ L/well of 1M HCl to stop After the reaction, the absorbance was read at 450 nm with a microplate reader (Thermo, Lux), and the data were analyzed.
  • HEK293T cells overexpressing human ERBB3 (293T-human ERBB3) were digested with trypsin, collected by centrifugation, adjusted for cell density with FACS buffer (1 ⁇ PBS containing 2% FBS), and then spread in 96-well U-bottom plates. Wells 1 x 10 5 to 2 x 10 5 cells. Centrifugation: 1200g for 5 minutes, discard the supernatant, add 100 ⁇ L of antibody solution that has been gradient diluted with FACS buffer, and incubate at 4°C for 1 hour.
  • Centrifuge 1200g, 5 minutes, discard the supernatant, wash the cells twice with FACS buffer, add the fluorescently labeled secondary antibody working solution PE anti-human IgG Fc Antibody (Biolegend, Cat# 409304) prepared in FACS buffer, and resuspend in 100 ⁇ L per well Cells were incubated at 4°C for 1 hour. Centrifugation: 1200g, 5 minutes, discard the supernatant. After washing the cells twice with FACS buffer, they were resuspended in PBS, and the fluorescence signal was detected by a flow cytometer Bio-Rad (ZE5), and the EC 50 concentration of the antibody-binding cells was analyzed by curve.
  • PE anti-human IgG Fc Antibody Biolegend, Cat# 409304
  • the results show that the antibody of the present invention can specifically bind to cells expressing human ERBB3.
  • Detect whether the antibody of the present invention can be endocytosed with human ERBB3 after binding to ERBB3, and evaluate it with human breast adenocarcinoma cell SK-Br-3 expressing ERBB3.
  • Cells were digested with trypsin, collected and resuspended in pre-cooled FACS buffer to adjust the cell concentration to 2 ⁇ 10 6 /mL.
  • Take the EP tube add 1 mL of cell suspension, centrifuge at 1500 rpm for 5 minutes, discard the supernatant, add 1 mL of the prepared antibody to be tested to resuspend the cells, the final concentration of the antibody is 20 ⁇ g/ml, and incubate at 4°C for 1 hour on a shaker.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un anticorps anti-ERBB3 ou un fragment de liaison à l'antigène de celui-ci, ainsi que son utilisation médicale, et en particulier un anticorps anti-récepteur ERBB3 complètement humanisé ou un fragment de liaison à l'antigène de celui-ci et son utilisation médicale. La présente invention concerne en outre une composition pharmaceutique comprenant l'anticorps anti-ERBB3 complètement humanisé ou un fragment de liaison à l'antigène de celui-ci, ainsi que son utilisation en tant que médicament anticancéreux.
PCT/CN2021/124031 2020-10-15 2021-10-15 Anticorps anti-erbb3 ou fragment de liaison à l'antigène de celui-ci et utilisation médicale associée WO2022078490A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202180050433.6A CN115843256A (zh) 2020-10-15 2021-10-15 抗erbb3抗体或其抗原结合片段及其医药用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011105695.1 2020-10-15
CN202011105695 2020-10-15

Publications (1)

Publication Number Publication Date
WO2022078490A1 true WO2022078490A1 (fr) 2022-04-21

Family

ID=81208919

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/124031 WO2022078490A1 (fr) 2020-10-15 2021-10-15 Anticorps anti-erbb3 ou fragment de liaison à l'antigène de celui-ci et utilisation médicale associée

Country Status (3)

Country Link
CN (1) CN115843256A (fr)
TW (1) TW202227504A (fr)
WO (1) WO2022078490A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023198138A1 (fr) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 Anticorps ou fragment de liaison à l'antigène de celui-ci et son utilisation médicale

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1214044C (zh) * 1996-03-27 2005-08-10 基因技术股份有限公司 ErbB3抗体
US20070122407A1 (en) * 1996-03-27 2007-05-31 Robert Akita ISOLATED NUCLEIC ACIDS, VECTORS AND HOST CELLS ENCODING ErbB3 ANTIBODIES
CN101674846A (zh) * 2007-02-16 2010-03-17 梅里麦克制药股份有限公司 ErbB3抗体及其用途
CN103562226A (zh) * 2011-03-11 2014-02-05 梅里麦克制药股份有限公司 使用egfr家族受体的抑制剂来治疗激素难治性乳腺癌
WO2015157634A1 (fr) * 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anticorps anti-erbb et leurs méthodes d'utilisation
WO2019175359A1 (fr) * 2018-03-14 2019-09-19 UltraHuman Thirteen Limited Anticorps anti-erbb3 désimmunisés
CN110650752A (zh) * 2017-03-31 2020-01-03 美勒斯公司 用于治疗具有NRG1融合基因的细胞的ErbB-2和ErbB3结合双特异性抗体

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1214044C (zh) * 1996-03-27 2005-08-10 基因技术股份有限公司 ErbB3抗体
US20070122407A1 (en) * 1996-03-27 2007-05-31 Robert Akita ISOLATED NUCLEIC ACIDS, VECTORS AND HOST CELLS ENCODING ErbB3 ANTIBODIES
CN101674846A (zh) * 2007-02-16 2010-03-17 梅里麦克制药股份有限公司 ErbB3抗体及其用途
CN103562226A (zh) * 2011-03-11 2014-02-05 梅里麦克制药股份有限公司 使用egfr家族受体的抑制剂来治疗激素难治性乳腺癌
WO2015157634A1 (fr) * 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anticorps anti-erbb et leurs méthodes d'utilisation
CN110650752A (zh) * 2017-03-31 2020-01-03 美勒斯公司 用于治疗具有NRG1融合基因的细胞的ErbB-2和ErbB3结合双特异性抗体
WO2019175359A1 (fr) * 2018-03-14 2019-09-19 UltraHuman Thirteen Limited Anticorps anti-erbb3 désimmunisés

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023198138A1 (fr) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 Anticorps ou fragment de liaison à l'antigène de celui-ci et son utilisation médicale

Also Published As

Publication number Publication date
TW202227504A (zh) 2022-07-16
CN115843256A (zh) 2023-03-24

Similar Documents

Publication Publication Date Title
TWI796328B (zh) Ｂ７-ｈ３抗體、其抗原結合片段及其醫藥用途
CN110366560B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
TWI673287B (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
US20200148778A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
CN112243443B (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
WO2019141268A1 (fr) Anticorps anti-4-1bb, fragment de liaison à l'antigène de celui-ci et utilisation médicale associée
CN114591434B (zh) 抗Siglec15抗体及其制备方法和用途
WO2021110095A1 (fr) Anticorps anti-gpc3, fragment de liaison à l'antigène de celui-ci, et son utilisation médicale
WO2021213245A1 (fr) Anticorps ou fragment de liaison à l'antigène, procédé de préparation correspondant et utilisations pharmaceutiques associées
WO2020156439A1 (fr) Anticorps anti-cd79b, fragment de liaison à l'antigène de celui-ci et utilisation pharmaceutique associée
WO2022078490A1 (fr) Anticorps anti-erbb3 ou fragment de liaison à l'antigène de celui-ci et utilisation médicale associée
TWI836070B (zh) 抗trop-2抗體、其抗原結合片段及其醫藥用途
WO2022144025A1 (fr) Anticorps de récepteur anti-erbb3 ou fragment de liaison à l'antigène de celui-ci et utilisation médicale associée
WO2021209066A1 (fr) Molécule spécifique de liaison à l'antigène, procédé de préparation correspondant et utilisation pharmaceutique associée
WO2023198138A1 (fr) Anticorps ou fragment de liaison à l'antigène de celui-ci et son utilisation médicale
TWI840399B (zh) 結合人il-4r的抗體、其抗原結合片段及其醫藥用途
WO2022078424A1 (fr) Anticorps anti-trop-2, fragment de liaison à l'antigène de celui-ci ou mutant de celui-ci, et utilisation médicale associée
CN115109157A (zh) 抗体或其抗原结合片段，其制备方法及医药用途
CN116478288A (zh) 红细胞弱结合型人源化cd47抗体及其应用
CN115947855A (zh) 抗cd24抗体的制备及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21879531

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21879531

Country of ref document: EP

Kind code of ref document: A1